TITLE

Exenatide + rosiglitazone added to metformin

PUB. DATE
August 2010
SOURCE
Clinical Cardiology Alert;Aug2010 Supplement, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on the efficacy of exenatide and rosiglitazone added to metformin for controlling glucose, with reference to a study by R. A. DeFronzo and colleagues, published in the 2010 issue of the journal "Diabetes Care."
ACCESSION #
53149139

 

Related Articles

  • Exenatide + rosiglitazone added to metformin. Kuritzky, Louis // Critical Care Alert;Aug2010 Primary Care Supp, p16 

    The article presents information on the treatment of type 2 diabetes with adequate lifestyle and metformin.

  • Exenatide + rosiglitazone added to metformin.  // Clinical Oncology Alert;Aug2010 Supplement, p16 

    The article discusses research being done on the effect of exenatide (EXE) and rosiglitazone (ROS) when added to metformin to control glucose in patients with type 2 diabetes (DM2) in reference to a study by R. A. DeFronzo et al. published in the 2010 issue of "Diabetes Care."

  • Metformin Still Ranked Favorably Among Diabetes Drugs.  // Journal of Gerontological Nursing;May2011, Vol. 37 Issue 5, p7 

    The article reports on research on diabetes medications that was published in the "Annals of Internal Medicine." The research found that many of the newest types of medications that are on the market in 2011 aren't necessarily the most effective and that one of the original drugs, metformin, is...

  • Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas. Chatterjee, Ranee; Edelman, David // JGIM: Journal of General Internal Medicine;Jun2016, Vol. 31 Issue 6, p650 

    A review of the article "Comparative effectiveness of insulin versus combination sulfonylurea and insulin: a cohort study of veterans with type 2 diabetes," by JY GYM Min, AM Hung, and CG Grijalva in "Journal of General Internal Medicine," doi: 10.1007/s11606-016-3633-2.

  • Once weekly exenatide vs sitagliptin or pioglitazone for type 2 diabetes. Kuritzky, Louis // Clinical Cardiology Alert;Nov2010 Clinical Brief, p21 

    The article discusses research being done on the effectiveness of using exenatide, sitagliptin or pioglitazone as an adjunct to metformin for type 2 diabetes treatment, which references a study by R. M. Bergenstall and colleagues in a 2010 issue of the journal "Lancet."

  • Once weekly exenatide vs sitagliptin or pioglitazone for type 2 diabetes. Kuritzky, Louis // Clinical Oncology Alert;Nov2010 Supplement 2, p21 

    The article presents the findings of a randomised trial which investigated the efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an add-on therapy for persons with type 2 diabetes, referencing a study by R. M. Bergenstal et al published in an issue of "Lancet."

  • Once weekly exenatide vs sitagliptin or pioglitazone for type 2 diabetes. Kuritzky, Louis // Critical Care Alert;Nov2010 Clinical Briefs Supplement, p21 

    The article focuses on the safety and efficacy of exenatide versus pioglitazone or sitagliptin in treating type 2 diabetes.

  • DIABETES FOUNDATION. Diabetes Treatment: Oral Agents. Fowler, Michael J. // Clinical Diabetes;Summer2010, Vol. 28 Issue 3, p132 

    The article discusses the use of oral agents including metformin, sulfonylureas and glinides in treatment of type 2 diabetes. It is stated that, metformin, which is used as the sole agent in the biguanide class of medications in the U.S., primarily decreases hepatic glucose output. Experts state...

  • S axagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults. Minze, Molly G.; Klein, Mary S.; Terrell, Brian T. // Clinical Medicine Insights: Endocrinology & Diabetes;2013, Issue 6, p15 

    Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics